About Freeline
Freeline is a company based in Stevenage (United Kingdom) founded in 2015 was acquired by Syncona in November 2023. Freeline has raised $273.69 million across 6 funding rounds from investors including Syncona, TD Securities and UCL Technology Fund. The company has 152 employees. Freeline has completed 1 acquisition, including SwanBio Therapeutics. Freeline offers products and services including FLT201, Gene Therapy for Parkinson's, and Gene Therapy for AMN. Freeline operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Stevenage, United Kingdom
- Employees 152
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website freeline.life
- Social LinkedIn
- Acquired by Syncona (Nov 2023)
- Legal Name Freeline Therapeutics Limited
- Date of Incorporation 19 Mar, 2015
- Jurisdiction STEVENAGE, HERTFORDSHIRE, ENGLAND
Products & Services of Freeline
Freeline offers a comprehensive portfolio of products and services, including FLT201, Gene Therapy for Parkinson's, and Gene Therapy for AMN.
Gene therapy candidate targeting Gaucher Disease through clinical trials.
Treatment aimed at modifying Parkinson's Disease progression.
First-in-class therapy for adrenomyeloneuropathy conditions.
Funding Insights of Freeline
Freeline has successfully raised a total of $273.69M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $125.51 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $273.69M
- Total Rounds 6
- Last Round Post-IPO — $125.51M
- First Round $37.08M
(Dec 2015)
- Investors Count 8
All 6 funding rounds of Freeline with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $125.51M | Post-IPO | – | – | – |
| Jun 2020 | $80M | Series C | – | Novo Holdings, Eventide Funds | |
| Dec 2019 | $40M | Series C | – | Syncona | – |
| May 2019 | $1.67M | Grant | – | – | |
| Jun 2018 | $116.61M | Series B | – | Syncona | |
| Dec 2015 | $37.08M | Series A | – | Syncona | – |
8 investors in total: 8 institutional.
Investors in Freeline
Freeline has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Syncona, TD Securities and UCL Technology Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
- | – | acornbioventures.com | - | |
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
Venture capital firm focused on physical and life sciences companies | 2015 | ucltf.co.uk | London, United Kingdom | |
Eventide Mutual Funds is managed by Eventide Asset Management, offering investment solutions. | – | eventidefunds.com | Boston, United States | |
Diversified investment management services are provided to institutional clients. | – | wellington.com | Boston, United States | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States | |
- | – | innovateuk.gov.uk | - |
Investor details for Freeline
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Freeline
32 people are tracked at Freeline (21 in leadership, 5 in board & advisors, 6 in team); the tracked headcount is 152.
| Name | Role | Group |
|---|---|---|
Michael Parini | CEO | Leadership |
Paul Schneider | CFO & Director | Leadership |
Nicole Jones | Chief People Officer | Leadership |
Pamela Foulds | Chief Medical Officer | Leadership |
Eileen McNeill | Senior Director, Head Of Research Project Management | Leadership |
Richard Lehane | Sr Director, Head Of IT | Leadership |
Lynn Donald | Senior Director, Clinical Operations | Leadership |
Laura Stikeleather | Executive Assistant: Chief Financial Officer | Leadership |
Erald Shehu | Scientific Director | Leadership |
Elyssa Reida | Executive Assistant To The CMO & Cpo, & Office Manager | Leadership |
Rose Sheridan | Head Of Research | Leadership |
Sean Lamont | Vice President Finance | Leadership |
Ron Katz | Vp, Head Of Business Development And Intellectual Property | Leadership |
Chip McCorkle | Vice President Legal | Leadership |
James Davies | Director, Corporate Development And Strategy, Chief Of Staff To CEO | Leadership |
Francesca Ferrante | VP Head Of Clinical Development And Pharmacovigilance | Leadership |
Yi Cui | Vice President, Head Of Clinical Drug Safety & Pharmacovigilance, Clinical And Medical | Leadership |
Egor Zhelezniak | Director, People Operations | Leadership |
Rachana Shah | Director Technical Operations | Leadership |
Tara Grindle | Global Talent & People Business Partner | Leadership |
12 more people are available in the full profile.
Complete people profiles for Freeline
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Freeline
Freeline has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SwanBio Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AAV-based gene therapy for neurological diseases is provided. | swanbiotx.com | Bala Cynwyd, United States | 2017 | Jun 2024 | •••• |
Complete acquisition details for Freeline
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Freeline
6 dated milestones of Freeline across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Freeline is founded.
- Funding First funding round of $37.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $125.5M.
- Exit Acquired by Syncona.
- Acquisition Acquires SwanBio Therapeutics.
Competitors of Freeline
Freeline operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases |
Detailed competitors of Freeline
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Freeline
Complete news archive for Freeline
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Freeline
10 companies that operate in the same segment as Freeline (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Freeline
Freeline was founded in 2015.
Freeline is headquartered in Stevenage, United Kingdom. It is registered at Stevenage, Hertfordshire, United Kingdom.
Michael Parini is the current CEO of Freeline.
Freeline is a funded company, having raised a total of $273.69M across 6 funding rounds to date. The company's 1st funding round was a Series A of $37.08M, raised on Dec 2015.
Freeline has 152 employees.
Annual revenue of Freeline is $435.87K as on Dec 31, 2018.
Freeline was founded in 2015 in Stevenage, United Kingdom, as a biotechnology company focused on gene therapy. A platform is offered to deliver therapeutic genes to the liver, enabling secretion of proteins for patients with hemophilia (FLT180a) and Fabry disease (FLT190). Lysosomal storage disorders are diagnosed, and clinical trial solutions are provided to support hemophilia management procedures.
Freeline's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Freeline offers FLT201, Gene Therapy for Parkinson's, and Gene Therapy for AMN.
Freeline has made 1 acquisition, including SwanBio Therapeutics.
Freeline has 8 investors. Key investors include Syncona, TD Securities, UCL Technology Fund, Novo Holdings, and Eventide Mutual Funds.
Freeline operates through Freeline Therapeutics Limited.